written on 19.02.2014

Chi-Med mulls independent China development of new drugs


The "standout performance" of its drug R&D division, led by Hutchison MediPharma, means that the group can now look at such independent activities for selected pipeline projects. "We will continue to negotiate more collaborations on our broader pipeline…

Latest Reports